Madrigal Pharmaceuticals Inc

MDGL

NASDAQ. Currency in USD

234.83 +171.03 ( +268.07% )

Real time prices: December 19

Market Cap.

4.02B

Beta (5Y monthly)

0.89 Price/Earnings

-

EPS (TTM)

-16.03

Forward Dividend

0.00 (0.00%)

Ex-Dividend Date

Volume

8.71M

1y Target Est.

152.58 Day's Range

191.49

236.39

52 Week's Range

54.34

236.39

Historical Summary

Performance

1 Month

222.57%

YTD

177.12%

1Y

202.77%

2Y

100.50%

41.63% ann.

3Y

164.48%

38.28% ann.

5Y

148.10%

19.93% ann.

EPS growth

1Y

-9.42%

2Y

-44.81%

25.72% ann.

3Y

-264.32%

-18.00% ann.

5Y

-531.10%

-33.95% ann.

10Y

53.69%

4.39% ann.

Share Buybacks

3 Months

-0.00%

6 Months

-0.00%

1Y

-2.79%

2Y

-10.71%

3Y

-10.95%

5Y

-38.17%

10Y

-886.81%

About Madrigal Pharmaceuticals Inc

Sector

Healthcare

Industry

Biotechnology

Website

https://www.madrigalpharma.com

Exchange

NASDAQ (XNAS)

Shares Outstanding

17.10M

Employees

71 Address

Four Tower Bridge, West Conshohocken, PA, United States, 19428

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.

Latest news

Madrigal Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

CONSHOHOCKEN, Pa., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage...
By GlobeNewswire Inc. - 20 weeks ago

MDGL 268.07%

Madrigal Pharmaceuticals Provides Clinical and Business Updates and Reports 2022 Second Quarter Financial Results

CONSHOHOCKEN, Pa., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical...
By GlobeNewswire Inc. - 25 weeks ago

MDGL 268.07%

Benzinga's Top Ratings Upgrades, Downgrades For July 8, 2022

Upgrades According to Wedbush, the prior rating for Diebold Nixdorf Inc (NYSE:DBD) was changed from...
By Benzinga - 29 weeks ago

Madrigal Pharmaceuticals Presents Late-Breaking Phase 3 NASH Data and Multiple Oral Abstracts at EASL’s International Liver Congress™

CONSHOHOCKEN, Pa., June 25, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical...
By GlobeNewswire Inc. - 31 weeks ago

MDGL 268.07%

Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences